SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Sea Ltd. is an internet and mobile platform company, which engages in the provision of online gaming services. It operates through the following segments: Digital Entertainment, E-Commerce, and Digital Financial Services. The Digital Entertainment segment offers and develops mobile and PC online games. The E-Commerce segment manages a third-party marketplace through the Shopee mobile app and websites that connect buyers and sellers. The Digital Financial Services segment includes a variety of payment services and loans to individuals and businesses through SeaMoney. Sea was founded by Xiao Dong Li, Gang Ye, and Jing Ye Chen on May 8, 2009 and is headquartered in Singapore.

Sea Ltd - ADR

Sea Ltd. is facing significant selling pressure as investors grapple with margin compression, intense regional competition, and ongoing frustration over management's capital allocation strategy. While some long-term investors highlight strong revenue growth and a massive addressable market, current sentiment is dominated by technical breakdowns and concerns that heavy investment in logistics could weigh on near-term profitability.

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG

CRISPR Therapeutics is trending as investors digest a recent $550 million convertible note offering, which some view as a strategic move to extend runway for clinical pipeline development despite immediate share price pressure. The community remains deeply divided between long-term bulls betting on a potential buyout or major trial catalysts later this year, and frustrated traders venting over persistent management-related sell-offs and the stock's struggle to sustain price momentum.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is experiencing heightened investor interest driven by anticipation for upcoming clinical data presentations and a potential BLA submission later this year. The community is actively discussing the stock's high short interest and limited effective float, fueling speculation about a possible short squeeze and long-term valuation potential relative to sector peers.

NuScale Power Corp. provides proprietary and innovative advanced small modular reactor (SMR) nuclear technology, with a mission to help power the global energy transition by delivering safe, scalable, and reliable carbon-free energy. Its products include VOYGR SMR Plants and Energy Exploration (E2) Centers. The company was founded by José N. Reyes in 2007 and is headquartered in Corvallis, OR.

NuScale Power Corporation - Ordinary Shares - Class A

NuScale Power Corp

NuScale Power is attracting intense community attention as part of a broader nuclear energy revival, fueled by growing demand for 24/7 power from AI data centers and new federal initiatives for space-based nuclear reactors. While some investors are accumulating shares on weakness and eyeing a long-term recovery, others are deeply concerned by the stock's significant decline, persistent short interest, and ongoing corporate divestment, leading to heated debates over whether this is a structural buying opportunity or a speculative value trap.

MercadoLibre, Inc. engages in the development of an online commerce platform with a focus on e-commerce and related services. It operates through the following geographical segments: Brazil, Argentina, Mexico, and Other Countries. The Other Countries segment refers to Chile, Colombia, Costa Rica, Dominican Republic, Ecuador, Panama, Peru, Bolivia, Honduras, Nicaragua, El Salvador, Guatemala, Paraguay, Uruguay, and the United States of America. Its products provide a mechanism for buying, selling, and paying as well as collecting, generating leads, and comparing lists through e-commerce transactions. The company was founded by Marcos Eduardo Galperin on October 15, 1999 and is headquartered in Montevideo, Uruguay.

MercadoLibre Inc

MercadoLibre is trending as investors debate the impact of high-conviction insider buying from executives and speculative interest regarding potential regional growth catalysts. Market participants remain focused on the company's long-term ecosystem dominance in Latin America versus near-term margin pressures stemming from aggressive reinvestment in logistics and fintech.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is seeing active community debate as investors weigh long-term utility goals against frustration over stagnant price action and the emergence of Janction. While some traders are focused on technical resistance levels and accumulation strategies, others are vocal about their skepticism regarding the project's roadmap and leadership communication.

Cava Group, Inc. is a holding company, which engages in the category-defining Mediterranean fast-casual restaurant brand, bringing together healthful food and bold, satisfying flavors at scale. It operates through the following segments: CAVA and CAVA Foods. The CAVA segment includes the operations of all company-owned CAVA restaurants. The CAVA Foods segment includes the production of dips and spreads used in CAVA restaurants as well as sales from the consumer-packaged goods (CPG) business. The company was founded by Brett Schulman, Ike Grigoropoulus, Dimitri Moshovitis, and Theodore Xenohristos in 2010 and is headquartered in Washington, DC.

Cava Group Inc

CAVA Group Inc

CAVA is trending following a strong quarterly earnings report that topped revenue and profit expectations, signaling robust growth in same-store sales and aggressive store expansion. Investors are actively debating the company's premium valuation compared to industry peers like Chipotle, with community sentiment split between enthusiasm for its rapid unit growth and skepticism regarding its long-term margin sustainability.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid Group is experiencing intense market volatility and a sharp sell-off following a series of major corporate announcements, including the appointment of a new CEO and a significant capital raise through a follow-on offering. Investors are expressing deep frustration over ongoing share dilution, while the community remains sharply divided between those viewing the current valuation as a distressed 'generational buying opportunity' and those warning of imminent bankruptcy and further reverse splits.

General Mills, Inc. engages in the manufacture and marketing of branded consumer foods sold through retail stores. Its product categories include snacks, ready-to-eat cereal, convenient meals, pet food, refrigerated and frozen dough, baking mixes and ingredients, yogurt, and ice cream. It operates through the following segments: North America Retail, International, North America Pet, and North America Foodservice. The North America Retail segment includes grocery stores, mass merchandisers, membership stores, natural food chains, drug, dollar and discount chains, convenience stores, and e-commerce grocery providers. The International segment refers to the retail and foodservice businesses outside of the US and Canada. The North America Pet segment includes pet food products sold in national pet superstore chains, e-commerce retailers, grocery stores, regional pet store chains, mass merchandisers, and veterinary clinics and hospitals. The North America Foodservice segment offers ready-to-eat cereals, snacks, refrigerated yogurt, frozen meals, unbaked and fully baked frozen dough products, baking mixes, and bakery flour. The company was founded by Cadwallader C. Washburn on June 20, 1928 and is headquartered in Minneapolis, MN.

General Mills, Inc.

General Mills is currently trending as investors weigh its attractive dividend yield against significant headwinds, including shifts in consumer preference due to weight-loss drugs and broader market rotation out of defensive staples. Community discussion remains heavily polarized, with many market participants viewing the stock as a contrarian 'value play' at multi-year lows, while others remain skeptical, citing concerns over high debt, falling sales volumes, and the risk of dividend cuts.

The Compound Governance Token is a governance token on the Compound Finance lending protocol, COMP allows the owner to delegate voting rights to the address of their choice; the owner’s wallet, another user, an application, or a DeFi expert. Anybody can participate in Compound governance by receiving delegation, without needing to own COMP.  Anybody with 1% of COMP delegated to their address can propose a governance action; these are simple or complex sets of actions, such as adding support for a new asset, changing an asset’s collateral factor, changing a market’s interest rate model, or changing any other parameter or variable of the protocol that the current administrator can modify.

Compound

Compound is generating buzz as investors speculate on a potential supply shock due to its limited 10 million token cap, while the community closely monitors potential institutional interest and upcoming decentralized finance (DeFi) developments. Despite varied sentiment regarding historical performance, the discussion is heavily fueled by anticipation of broader market momentum and the potential for a reversal as traders track key support and resistance levels.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Last month, the company said that SLS009 blocks key survival pathways that normally shield acute myeloid leukemia cells from natural programmed cell death, making them more vulnerable.</li><li>Pharmacodynamic changes were observed in AML cells as early as eight hours after treatment and became more pronounced over time, the company noted.</li><li>Meanwhile, Sellas’s late-stage trial of its lead candidate GPS in Acute Myeloid Leukemia is advancing toward final analysis.</li></ul>Shares of Sellas Life Sciences Group Inc. (SLS) closed up 6% and edged up 2% after-hours on Friday, garnering heavy retail interest as investors anticipated upcoming data updates on its pipeline at the American Association for Cancer Research.According to Stocktwits platform data, retail chatter increased 36% over the past day, rising from ‘low’ to ‘normal’ levels.Sellas is slated to present preclinical data on its experimental cancer therapy SLS009 in a poster session at the conference which started on April 17 and is slated to go till April 22 at the San Diego Convention Center. Sellas will make its presentation on April 21.<h2 class="st-heading-2">Pipeline Optimism</h2>Last month, the company said that SLS009 blocks key survival pathways that normally shield acute myeloid leukemia (AML) cells from natural programmed cell death, making them more vulnerable. Pharmacodynamic changes were observed in AML cells as early as eight hours after treatment and became more pronounced over time, the company noted.“The ability to lower apoptotic threshold in AML cells by suppressing key survival pathways and enhancing potency with repeated exposure further supports the development of SLS009, including in combination regimens,” said Dragan Cicic, Chief Development Officer of SELLAS.Sellas’s lead candidate, GPS, meanwhile, is being evaluated for its potential as a monotherapy and in combination with other therapies to address a broad spectrum of blood malignancies and solid tumor indications.The company’s late-stage trial of GPS in Acute Myeloid Leukemia is advancing toward final analysis. The final analysis is slated for when the company records the 80th patient death in the trial. In December, the company announced that 72 events had been completed and it will announce when the 80th event occurs. With event-driven trials like Sellas’s, the delay highlights longer survival, indicating potential for the therapy.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around SLS stock rose from ‘bearish’ to ‘neutral’ territory over the past 24 hours.A Stocktwits user said that the stock has two near-term catalysts in terms of the upcoming conference and update on the GPS program in AML.<stembedurl>https://www.stocktwits.com/55X_ROI_Q1_2026/message/650652881</stembedurl>Yet another sounded optimistic for the company’s pipeline, highlighting the many designations granted to Sellas’s experimental therapies.<stembedurl>https://www.stocktwits.com/gata2016/message/650649884</stembedurl><a href="https://stocktwits.com/symbol/SLS">SLS stock</a> has nearly quadrupled over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/cadl-stock-on-track-for-best-day-in-nearly-16-months-whats-driving-the-rally/cZJyGq6RIUn">CADL Stock On Track For Best Day In Nearly 16 Months — What’s Driving The Rally?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Last week, Baird maintained AYI’s ‘neutral’ rating but cut price target to $320 from $375. (Representative image: Getty Images)

SLS Stock Sparks Retail Buzz Ahead of AACR Presentation On Experimental Cancer Therapy

Sellas is slated to announce preclinical data on its experimental cancer therapy SLS009 in a poster session at the conference which started on April 17 and is slated to go till April 22 at the San Diego Convention Center.

Equity

Sellas is slated to announce preclinical data on its experimental cancer therapy SLS009 in a poster session at the conference which started on April 17 and is slated to go till April 22 at the San Diego Convention Center.


<ul class="summary-bullets"><li>In a post on X on Friday, Paul Peter Tak, chief executive officer of Candel Therapeutics, highlighted the story of Kyle Donahue, a five-year survivor of recurrent glioblastoma featured in Parade magazine.</li><li>Candel investors are now awaiting further updates on the company’s planned late-stage trial in non-small cell lung cancer and other programs including CAN-3110 for glioblastoma.</li><li>New data from the randomized late-stage trial of CAN-2409 in localized prostate cancer is scheduled for presentation at the American Urological Association (AUA) 2026 meeting in May.</li></ul>Shares of Candel Therapeutics (CADL) jumped 24% on Friday as investors await upcoming clinical data readouts and process positive media coverage of a recurrent glioblastoma patient who took part in one of the company’s clinical trials.The stock is now on track to record its best day since December 2024, if gains hold.<h2 class="st-heading-2">Positive Media Coverage</h2>In a post on X on Friday, Paul Peter Tak, chief executive officer of Candel Therapeutics, highlighted the story of Kyle Donahue, a five-year survivor of recurrent glioblastoma, featured in Parade magazine.Donahue, who was initially given only months to live after her diagnosis, participated in a clinical trial of the company’s investigational viral immunotherapy CAN-3110. Tak described the case as both deeply personal and scientifically meaningful, noting that such outcomes underscore the potential of viral immunotherapies to reshape the tumor microenvironment, activate durable immune responses, and represent a possible turning point in a disease where progress has long been elusive.<h2 class="st-heading-2">Upcoming Catalysts</h2>Candel investors are now awaiting further updates on the company’s planned late-stage trial in non-small cell lung cancer and other programs including CAN-3110 for glioblastoma. New data from the randomized late-stage trial of CAN-2409 in localized prostate cancer is scheduled for presentation at the American Urological Association (AUA) 2026 meeting in May.To add to the momentum, last month, the company announced positive updates for its lead candidate CAN-2409 in patients with advanced non-small cell lung cancer. The company said that extended long-term survival was observed after an additional year of follow-up in an ongoing phase 2a clinical trial, with 50% of 46 patients treated with CAN-2409 surviving beyond 24 months.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around CADL stock jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘extremely high’ levels.A few Stocktwits users expressed optimism for an upcoming buyout or partnership for the company.<stembedurl>https://www.stocktwits.com/drizz/message/650628803</stembedurl><stembedurl>https://www.stocktwits.com/gusm17/message/650618195</stembedurl>Another highlighted the positive press published on Parade, terming it “incredibly positive.”<stembedurl>https://www.stocktwits.com/pyroclast/message/650627286</stembedurl><a href="https://stocktwits.com/symbol/CADL">CADL stock</a> has gained 40% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/omer-stock-on-track-for-best-week-in-nearly-four-months-after-receiving-permanent-reimbursement-code-for-treatment/cZJUzYKRIUj">OMER Stock On Track For Best Week In Nearly 4 Months After Receiving Permanent Reimbursement Code For Treatment</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

CADL Stock On Track For Best Day In Nearly 16 Months — What’s Driving The Rally?

Candel stock is rallying on the heels of positive media coverage of a recurrent glioblastoma patient who took part in one of the company’s clinical trials.  

<ul class="summary-bullets"><li>The company said the move reduces administrative hurdles by facilitating easier claims processing for hospitals and clinics.</li><li>Yartemlea is the first and only FDA-approved medicine for hematopoietic stem cell transplant-associated thrombotic microangiopathy.</li><li>The company is now eyeing an approval for the treatment by the European Medicines Agency by mid-2026.</li></ul> Shares of Omeros Corp. (OMER) are on track to close their best week since late December, if gains hold, after the U.S. Centers for Medicare and Medicaid Services assigned a permanent J-code for its recently-approved treatment Yartemlea.Yartemlea is the first and only approved medicine for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). The condition can hit people after a stem cell or bone marrow transplant and is a rare, severe, and potentially fatal complication where microscopic blood clots form in small vessels, damaging organs, particularly the kidneys and brain.The company said on Thursday that the J-code will become effective on July 1.<h2 class="st-heading-2">What Is The J-Code?</h2>A J-code is an official “billing sticker” that doctors and hospitals use when they give a patient non-orally administered medications, such as injections, infusions, and chemotherapy. A permanent J-code is designed to simplify billing and speed up reimbursement for a treatment when used by patients covered by Medicare, Medicaid and most commercial insurance plans.Omeros said the move reduces administrative hurdles by facilitating easier claims processing for hospitals and clinics.“For patients with TA-TMA, access to effective treatment without unnecessary delay is critical,” said CEO Gregory A. Demopulos. “The assignment of a permanent, product-specific J-code for YARTEMLEA establishes a clear and consistent reimbursement pathway across payors, reducing administrative burden, supporting faster access for patients, and delivering more predictable reimbursement for providers.”The U.S. Food and Drug Administration approved Yartemlea in December for the treatment of TA-TMA in adults and children aged two years and older. The company is now eyeing an approval for the treatment by the European Medicines Agency by mid-2026.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around OMER stock stayed within the ‘bullish’ territory over the past 24 hours, while message volume remained at ‘low’ levels.A Stocktwits user highlighted the company’s partnership with Danish drugmaker Novo Nordisk (NVO).<stembedurl>https://www.stocktwits.com/resq1/message/650620063</stembedurl>Omeros and Novo entered into a definitive asset purchase and license agreement in October for the candidate drug zaltenibart in clinical development for rare blood and kidney disorders. Under the deal, Omeros is eligible to receive up to $2.1 billion, including milestone payments.Yet another Stocktwits user applauded the J-code as “actually huge” and voiced optimism for it driving commercial acceleration of Yartemlea.<stembedurl>https://www.stocktwits.com/mjk49/message/650580855</stembedurl><a href="https://stocktwits.com/symbol/OMER">OMER stock</a> has gained about 97% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/pbm-stock-on-track-for-best-week-on-over-2-years/cZJUwtIRIUf">PBM Stock On Track For Best Week In Over 2 Years On Hopes For Upcoming Executive Order To Ease Ibogaine Research</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Omeros Corporation logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

OMER Stock On Track For Best Week In Nearly 4 Months After Receiving Permanent Reimbursement Code For Treatment

Omeros said that the U.S. Centers for Medicare and Medicaid Services assigned a permanent J-code for its recently-approved treatment Yartemlea.

<ul class="summary-bullets"><li>UBS stated in its note that the competitive intensity in the battery energy storage systems space is increasing.</li><li>The firm cited the Trump administration’s tax policy, which incentivizes auto manufacturers to shift from battery production for electric vehicles to utility-scale BESS.</li><li>UBS expects an oversupply of BESS starting in 2027, which will push costs down and increase pressure on Fluence Energy’s margins.</li></ul>Shares of Fluence Energy Inc. (FLNC) could be in for further decline after falling more than 24% year to date, with UBS analysts flagging concerns about battery oversupply.According to TheFly, UBS downgraded Fluence Energy to ‘Sell’ from ‘Neutral’ and lowered its price target by 64% to $8 from $22. The firm’s new price target implies a 43% downside from Fluence Energy’s Thursday closing price.<a href="https://stocktwits.com/symbol/FLNC">Fluence Energy shares</a> were down more than 9% in Friday’s pre-market trade.<h2 class="st-heading-2">UBS Highlights Increasing Competitive Intensity</h2>UBS stated in its note that competitive intensity in the battery energy storage systems (BESS) space is increasing, citing the Trump administration’s tax policy that incentivizes auto manufacturers to shift production from batteries for electric vehicles to utility-scale BESS.The firm expects an oversupply of BESS starting in 2027, which will push costs down and thereby increase pressure on Fluence’s margins. UBS added that the market currently “significantly underappreciates” the manufacturing capacity additions of BESS due to U.S. tax policies for the sector.Analysts at Goldman Sachs also trimmed their price target for Fluence Energy to $20 from $28 while keeping a ‘Buy’ rating on the stock. The firm stated that it expects the first quarter (Q1) to be a “noisy” one for the company.Barclays analysts noted that while Fluence Energy has resolved the tax credit risk after its supplier retained compliance with the Foreign Entity of Concern rules, the Middle East shipping disruptions due to the Iran war could result in Fluence missing second-quarter (Q2) sales estimates. Barclays lowered its price target for Fluence Energy to $16 from $20, while maintaining an ‘Equal Weight’ rating.Fluence Energy reaffirmed earlier this month the continued availability of its U.S.-manufactured products that qualify for tax incentives under the One Big Beautiful Bill Act.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/FLNC">Fluence Energy</a> trended in the ‘bullish’ territory, with message volumes at ‘high’ levels at the time of writing.<a href="https://stocktwits.com/symbol/FLNC">FLNC stock</a> is down 24% year-to-date, but up 312% over the past 12 months. The iShares Russell 2000 ETF (IWM) is up 46% over the past 12 months, while the Vanguard Small-Cap Growth Index Fund ETF (VBK) is up 40%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/envb-stock-on-track-worst-decline-10-weeks-enveric-private-placement/cZJUl4KRIx0">ENVB Stock Is On Track For Its Worst Decline In Over 10 Weeks On Discounted Offering – But Retail Remains Upbeat</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

 In this photo illustration, the Fluence Energy logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

FLNC Stock Has Dropped 24% This Year — And More Pain May Be Coming Due To Trump Administration’s Tax Policies

UBS downgraded Fluence Energy to ‘Sell’ from ‘Neutral’ and lowered its price target by 64% to $8 from $22, which implies a 43% downside from the closing price on Thursday.

<ul class="summary-bullets"><li>Earlier this week, Credo announced an acquisition of DustPhotonics, a developer of Silicon Photonics Photonic Integrated Circuit technology for optical transceivers.&nbsp;</li><li>Goldman Sachs analyst James Schneider noted Credo's acquisition of DustPhotonics, saying the deal would accelerate its expansion into optical networking.&nbsp;</li><li>According to data from Koyfin, analysts covering CRDO stock have a 12-month average price target of $204.59, indicating an upside potential of about 28.7%.</li></ul>Shares of Credo Technology Group Holding (CRDO) have rallied more than 46% in the past 5 days, gaining attention from investors and Wall Street analysts alike.The company has been riding the wave of optimism over its <a href="https://stocktwits.com/news-articles/markets/equity/crdo-stock-soars-post-market-on-dustphotonics-acquisition/cZJ8QyZRIuy">acquisition of DustPhotonics</a>, a developer of Silicon Photonics Photonic Integrated Circuit (SiPho PIC) technology for optical transceivers, announced earlier this week.Following the news, Jefferies raised its price target on Credo to $225 from $175, while maintaining a ‘Buy’ rating on the stock, <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.investing.com/news/analyst-ratings/jefferies-raises-credo-technology-stock-price-target-on-optics-growth-93CH-4619456">according</a> to Investing.com. The updated target represents an upside potential of about 41.6% from the last close.Earlier in the day, Goldman Sachs also raised the price target on Credo to $170 from $150 and kept a ‘Buy’ rating on its shares, as per TheFly.<h2 class="st-heading-2">Street Consensus</h2>Jefferies said that it increased its estimates after Credo’s acquisition of DustPhotonics and the company’s guidance for more than $500 million in total Optics revenue for fiscal 2027. The analyst expects Credo’s Optics business in FY27 to generate approximately $125 million in Optical DSP revenue, more than $300 million in ZF Optics, and approximately $75 million in standalone PIC revenue.Goldman Sachs analyst James Schneider also noted Credo's acquisition of DustPhotonics, saying that the deal would accelerate its expansion into optical networking and strengthen confidence in its diversification beyond copper-based active electrical cables, with improved visibility toward its $500 million optical revenue target by FY27, the analyst said.Meanwhile, Bank of America raised its price target on the company to $210 from $160 and kept a ‘Buy’ rating on the shares after the acquisition. Rosenblatt analyst Mike Genovese also raised the firm's price target on Credo to $175 from $125 and kept a ‘Neutral’ rating on the shares.According to data from Koyfin, 16 out of 17 analysts covering CRDO stock have a ‘Buy’ or higher rating on it, with a 12-month average price target of $204.59, indicating an upside potential of about 28.7%.<h2 class="st-heading-2">Stronger AI Connectivity</h2>Credo’s acquisition of DustPhotonics is aimed at strengthening its optical interconnect roadmap and expanding its footprint in the global optical market. DustPhotonics’ silicon photonics technology will enhance performance, lower costs, and improve reliability for AI data centers, while boosting Credo’s ZeroFlap platform and reducing supply dependencies, the company said.Credo also said that it sees this as a key inflection point, expecting its optical business to surpass $500 million in revenue by FY27, supported by growing hyperscale AI demand. CEO William Brennan called the deal a defining step toward leading AI connectivity.<h2 class="st-heading-2">Retail Reaction</h2>On Stocktwits, retail sentiment around CRDO stock was in the ‘extremely bullish’ territory amid ‘extremely high’ message volumes at the time of writing. Retail chatter around the stock has increased 79% in the past week.While <a href="https://stocktwits.com/symbol/CRDO">CRDO shares</a> closed down 5.6% on Thursday, they have rallied more than 321% in the past year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Credo Technology logo is displayed on a smartphone screen

CRDO Stock Has Surged 46% In The Past 5 Days — Does It Have Room For More Upside?

Jefferies raised its price target on Credo Technology to $225 from $175, indicating an upside potential of about 41.6% from last close. 

<ul class="summary-bullets"><li>Quantum stocks have been on an upswing over the past few trading sessions, with AI bellwether Nvidia’s Ising launch earlier this week reigniting momentum in the sector.</li><li>D-Wave Quantum CEO Alan Baratz told Yahoo Finance during an interview on Thursday that the company has already crossed the “ChatGPT moment” in quantum computing.</li><li>He credited this to a method known as quantum annealing, which uses quantum physics to find the problem's low-energy states.</li></ul>Shares of D-Wave Quantum Inc. (QBTS) gained nearly 8% in Thursday’s pre-market trade&nbsp;and are on track to cross the 100-day moving average for the first time since January this year.If D-Wave shares continue the pre-market momentum through the day, this would be the fifth consecutive day of gains for the company’s stock.<a href="https://stocktwits.com/symbol/NVDA">D-Wave shares</a> have surged more than 43% over the previous five trading sessions.<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_04_16_at_7_01_31_AM_png_ddff2f3957.webp" alt="Screenshot 2026-04-16 at 7.01.31 AM.png" width="3326" height="1822"><figcaption>Source: TradingView</figcaption></figure><h2 class="st-heading-2">What Is Fueling The QBTS Rally?</h2>Quantum stocks have been on an upswing over the past few trading sessions, with AI bellwether Nvidia Corp.’s (NVDA)&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/jensen-huang-nvidia-ising-quantum-stocks-qbts-rgti-qubt-soar/cZJqfdwRIvd">Ising launch</a> earlier this week bringing back the momentum in the sector.On the sidelines of the Semafor World Economic Summit, D-Wave Quantum CEO Alan Baratz told Yahoo Finance&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://finance.yahoo.com/news/d-wave-ceo-says-quantum-computing-is-already-past-its-chatgpt-moment-214253705.html">during</a> an interview on Thursday that the company has crossed the “ChatGPT moment” for quantum computing already.Baratz credited this to a method known as quantum annealing, which uses quantum physics to find a problem's low-energy states. This technique is then used to arrive at the optimal or a near-optimal combination of elements. D-Wave’s computers are the most famous example of quantum annealers.D-Wave’s technology is currently being used in cellular networks and pharmaceutical supply chains.“For annealing, we've hit that point. For gate model systems. We're still a few years away from it,” Baratz added, while noting that it needs some more engineering.<h2 class="st-heading-2">Why Is This Important?</h2>D-Wave’s approach addresses the critical power-efficiency challenge currently facing the AI industry.Baratz stated in the interview that D-Wave’s quantum computers draw only 10 kilowatts to solve a problem and that the company’s technology can provide a solution within minutes, while a massive GPU cluster would require the “world’s power” and millions of years to achieve the same.On Tuesday, while announcing Ising, Nvidia CEO Jensen Huang stated that AI is essential to making quantum computing practical, as Nvidia’s new open AI model aims to help enterprises turn quantum processors into large-scale, reliable computers.“With Ising, AI becomes the control plane — the operating system of quantum machines — transforming fragile qubits to scalable and reliable quantum-GPU systems,” Huang said.This comes at a time when AI is expected to drive a surge in global electricity demand. According to an April 2025&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.iea.org/news/ai-is-set-to-drive-surging-electricity-demand-from-data-centres-while-offering-the-potential-to-transform-how-the-energy-sector-works">report</a> by the International Energy Agency, electricity demand from data centers worldwide is projected to more than double by 2030, to 945 terawatt-hours.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/QBTS">QBTS</a> trended in the ‘extremely bullish’ territory, with message volumes at ‘extremely high’ levels at the time of writing.One bullish user stated that quantum technology and nuclear are the future and hope of humanity.<stembedurl>https://stocktwits.com/QuantumKVY/message/650438448</stembedurl><a href="https://stocktwits.com/symbol/QBTS">QBTS stock</a> is down 20% year-to-date, but up 201% over the past 12 months. The iShares Russell 2000 ETF (IWM) is up 44% over the past 12 months, while the Vanguard Total Stock Market Index Fund ETF (VTI) is up 31%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-is-myse-stock-soaring-today/cZJvidNRID3">MYSE Stock Is Up More Than 200% Pre-Market Today — What’s Fueling The Rally?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, D-Wave Systems Inc. logo of a Canadian quantum computing company is seen on a smartphone screen. 

QBTS Stock On Track To Cross 100-DMA For First Time Since January After Gaining 43% In 5 Days — What Is Powering The Surge?

If D-Wave shares continue the pre-market momentum through the day, this would be the fifth consecutive day of gains for the stock.

Peak of Iran War Priced-In? Low-P/E High Momentum ETFs in Focus 

Markets may have priced in peak Iran war fears. With volatility easing, low P/E, high-momentum ETFs are emerging as smart bets for near-term gains.

<ul class="summary-bullets"><li>Credo said that it will pay $750 million in cash upfront and about 0.92 million shares of Credo common stock for DustPhotonics’ acquisition.</li><li>The transaction is expected to close in the second quarter of calendar year 2026.&nbsp;</li><li>Prior to the deal announcement, Jefferies initiated coverage of Credo Technology with a ‘Buy’ rating and $175 price target on Monday.</li></ul>Shares of Credo Technology Group Holding (CRDO) surged more than 10% in Monday’s extended trading hours after the company announced the acquisition of DustPhotonics, a developer of Silicon Photonics Photonic Integrated Circuit (SiPho PIC) technology for optical transceivers.Credo said that it will pay $750 million in cash upfront and nearly 1 million shares of Credo common stock for DustPhotonics’ purchase. Credo said that it may also pay incremental contingent consideration of up to approximately 3.21 million shares in addition, based on the achievement of certain financial milestones.The semiconductor company said that the deal will be accretive to adjusted earnings per share in its fiscal 2027.The transaction is expected to close in the second quarter of calendar year 2026.<h2 class="st-heading-2">Deal Rationale</h2>The acquisition will accelerate Credo's optical interconnect roadmap and expand its served addressable market in the global optical industry. DustPhotonics brings advanced silicon photonics (SiPho PICs) enabling higher speeds, lower costs, and improved reliability for AI data centers, the company said.Integrating these capabilities will boost Credo’s ZeroFlap platform, reduce supply dependencies, and accelerate innovation.Credo said that it believes it has reached an inflection point in its optical business, and the acquisition of DustPhotonics will help its optical portfolio generate more than $500 million in revenue in fiscal 2027, driven by strong customer traction and expanding adoption across hyperscale AI deployments, the company said.William Brennan, Chairman, and CEO, said the deal was “a defining step in Credo’s strategy to lead across the full spectrum of AI connectivity.”<h2 class="st-heading-2">Analyst Confidence</h2>Prior to the deal announcement, Jefferies initiated coverage of Credo Technology with a ‘Buy’ rating and $175 price target on Monday. The analyst said that Credo offered a "meaningful opportunity” to invest in a premium growth company that was trading at a significantly discounted valuation.The analyst said that it sees a "significant disconnect" between the market's perception of Credo's AI opportunity over the next several years relative to its actual opportunity.As per data from Koyfin, analysts have a 12-month average price target of $197.94 on the company’s shares, representing an upside potential of 47.32% from the last close.<h2 class="st-heading-2">Retail Reaction</h2>On Stocktwits, retail sentiment around CRDO shares jumped from ‘neutral’ to ‘bullish’ over the past day, while message volumes surged from ‘low’ to ‘high’ levels.One bullish user called the deal a “Massive Acquisition Move,” while highlighting the key takeaways.<stembedurl>https://stocktwits.com/BottomFisher_/message/650164177</stembedurl>Another user predicted the stock would go back to $200 levels, where it was trading at around December 2025.<stembedurl>https://stocktwits.com/m_23nyc/message/650164814</stembedurl><a href="https://stocktwits.com/symbol/CRDO">CRDO stock</a> has rallied more than 243% in the past year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

CRDO Stock Soars Post-Market On DustPhotonics Acquisition: Retail Eyes Surge To Over $200 

Credo Technology said that it believes it has reached an inflection point in its optical business, and the DustPhotonics deal will help its optical portfolio generate more than $500 million in revenue in fiscal 2027.

<ul class="summary-bullets"><li>Spyre is looking forward to developing the drug as a single treatment, as well as in combination with its investigational antibodies SPY002 or SPY003.</li><li>TD Cowen says Spyre Therapeutics' data "strengthened our confidence in an already great dataset" for SPY001.</li><li>Leerink continues to view the trial data as a best-case outcome for SPY00, one which derisks both its potential as a monotherapy and backbone in future combination regimens.</li></ul>Shares of Spyre Therapeutics Inc. (SYRE) closed up 23% on Monday after several analysts upped their price targets on the stock on the heels of positive ulcerative colitis trial data, with several noting the company’s experimental drug’s potential against Takeda’s Entyvio.The stock marked its highest single-day gain on Monday since June 2023.Earlier in the day, Spyre announced positive data from part A of its phase 2 trial of SPY001 in the treatment of moderate-to-severely active ulcerative colitis. The company said that the trial met its primary endpoint of statistically significant reduction in disease activity.The drug was further well tolerated though six subjects experienced treatment-emergent adverse events, including a serious event which the company deems as not related to the drug.Spyre is looking forward to developing the drug as a single treatment as well as in combination with its investigational antibodies SPY002 or SPY003.<h2 class="st-heading-2">Analyst Take Away</h2>TD Cowen said Spyre Therapeutics' data "strengthened our confidence in an already great dataset" for SPY001. The firm has a ‘Buy’ rating on Spyre.Wedbush analyst David Nierengarten, meanwhile, raised the firm's price target on Spyre to $80 from $65 and kept an ‘Outperform’ rating on the shares. Spyre's SPY001 monotherapy surpassed historical benchmarks for Takeda's (TAK) Entyvio with 40% clinical remission and 51% endoscopic improvement, yielding an anticipated upside scenario, the analyst told investors in a research note.Leerink, which also has an ‘Outperform’ rating on the stock, raised the firm's price target on Spyre Therapeutics to $106 from $49. Leerink continues to view the trial data as a best-case outcome for SPY001, one which derisks both its potential as a monotherapy and backbone in future combination regimens. The target change reflects the firm's increased conviction and higher probability of success for SPY001 opportunities in UC and Crohn's disease, it said.Overall, the firm believes these "striking initial” study results represent best case data for SPY001, suggesting positively differentiated efficacy vs. Entyvio across a broad range of objective and symptomatic measures. The data position SPY001 as a leading agent in this multi-billion-dollar class, argues Leerink.Stoked by the data, BTIG analyst Julian Harrison also raised the firm's price target on Spyre to $98 from $70, and kept a ‘Buy’ rating on the shares while raising the firm's view of the odds of success for SPY001 combos in UC to 80% following the results.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around SYRE stock jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume jumped from ‘high’ to ‘extremely high’ levels.<a href="https://stocktwits.com/symbol/SYRE">SYRE stock</a> has gained nearly 400% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/eras-stock-slumps-against-rvmd-rally-analyst-stays-bullish/cZJ8IHGRIuH">ERAS Stock Slumps Against RVMD Rally — Analyst Stays Bullish</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

SYRE Stock Marks Best Session In About 3 Years — Here’s Why 

Shares of Spyre Therapeutics Inc. (SYRE) closed up 23% on Monday after several analysts upped their price targets on the stock on the heels of positive ulcerative colitis trial data

Earlier in the day, Spyre said that part of its phase 2 ulcerative colitis trial met its primary endpoint of statistically significant reduction in disease activity.


Could Investing $10,000 in IWM Make You a Millionaire?

Key PointsThe iShares Russell 2000 ETF has delivered average annual returns of 8.06% for almost 26 years...

iShares Trust - iShares Russell 2000 ETF

Bullish continuation

Sideways chop

Fade lower

Full reversal

The market rebounded fast this week — what’s your call for next week?

Stocktwits

Stocktwits Polls

iShares Russell 2000 ETF

A growing crowd of retail investors is expressing disbelief at the market's inability to see a red day or significant pullback.

Discussions are dominated by the impact of geopolitical tension and ceasefire headlines on market pumps and asset pricing.

Retail traders are increasingly pointing to computer algorithms as the primary driver behind the consistent and relentless daily market push.

Persistent gains are putting massive pressure on bears, leading to aggressive short covering and warnings to avoid betting against the momentum.

IWM
iShares Russell 2000 ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest IWM News

IWMiShares Russell 2000 ETF